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Histone deacetylase inhibitors sodium butyrate and valproic acid
delay spontaneous cell death in purified rat retinal ganglion cells
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Purpose:  Histone  deacetylase  inhibitors  (HDACi)  have  neuroprotective  effects  under  various  neurodegenerative
conditions, e.g., after optic nerve crush (ONC). HDACi-mediated protection of central neurons by increased histone
acetylation has not previously been demonstrated in rat retinal ganglion cells (RGCs), although epigenetic changes were
shown to be associated with cell death after ONC. We investigated whether HDACi can delay spontaneous cell death in
purified rat RGCs and analyzed concomitant histone acetylation levels.
Methods: RGCs were purified from newborn (postnatal day [P] 0–P2) rat retinas by immunopanning with antibodies
against Thy-1.1 and culturing in serum-free medium for 2 days. RGCs were treated with HDACi, each at several different
concentrations: 0.1–10 mM sodium butyrate (SB), 0.1–2 mM valproic acid (VPA), or 0.5–10 nM trichostatin A (TSA).
Negative controls were incubated in media alone, while positive controls were incubated in 0.05–0.4 IU/µl erythropoietin.
Survival was quantified by counting viable cells using phase-contrast microscopy. The expression of acetylated histone
proteins (AcH) 3 and 4 was analyzed in RGCs by immunohistochemistry.
Results: SB and VPA enhanced RGC survival in culture, with both showing a maximum effect at 0.1 mM (increase in
survival to 188% and 163%, respectively). Their neuroprotective effect was comparable to that of erythropoietin at 0.05 IU/
µl. TSA 0.5–1.0 nM showed no effect on RGC survival, and concentrations ≥5 nM increased RGC death. AcH3 and AcH4
levels were only significantly increased in RGCs treated with 0.1 mM SB. VPA 0.1 mM produced only a slight effect on
histone acetylation.
Conclusions: Millimolar concentrations of SB and VPA delayed spontaneous cell death in purified RGCs; however,
significantly increased histone acetylation levels were only detectable in RGCs after SB treatment. As the potent HDACi
TSA was not neuroprotective, mechanisms other than histone acetylation may be the basis on which SB and VPA are
acting in this model. Additional studies are necessary to identify HDACi-targeted genes and pathways involved in RGC
protection.
Transcription in eukaryotes is a highly regulated process,
and acetylation is now known to play a major role in its
epigenetic modification [1]. The acetylation or deacetylation
of  histone  N-terminal  tails  alters  the  interaction  between
histones  and  DNA  in  chromatin,  and  this  chromatin
remodeling has been identified as a key step in the regulation
of  gene  expression  [2,3].  In  general,  hyperacetylation  is
associated  with  transcriptional  activation,  whereas
hypoacetylation  is  associated  with  repression.  Histone
acetyltransferases (HAT) and histone deacetylases (HDAC)
represent two enzyme classes that balance the acetylation
status in neurons. This acetylation homeostasis is impaired
toward deacetylation in neurodegenerative diseases, such as
amyotrophic  lateral  sclerosis,  Alzheimer  disease,  and
Parkinson disease [4,5].
Drugs  that  reduce  histone  deacetylation  in  diseased
neurons may restore transcriptional balance and hence delay
or prevent  cell  degeneration.  Such  compounds,  known  as
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histone deacetylase inhibitors (HDACi), affect histones as
well as transcription factors that are regulated by acetylation
[6]. HDACi are divided into four groups: 1. short-chain fatty
acids (e.g., sodium butyrate [SB], valproic acid [VPA]), 2.
hydroxamic acids (e.g., trichostatin A [TSA], suberoylanilide
hydroxamic  acid  [SAHA]),  3.  cyclic  tetrapeptides,  and  4.
benzamides [1]. SB, first synthesized in 1949, and VPA, an
anti-epileptic drug, were the first known HDACi and, together
with  TSA,  recently  attracted  attention  as  potentially
neuroprotective drugs [7]. It has been suggested that their
action is linked to a large extent to direct inhibition of HDAC
[8],  causing  histone  hyperacetylation.  However,  the
underlying  molecular  mechanisms  are  still  not  fully
understood.
In in vitro experiments HDACi protected neurons from
glutamate-induced  excitotoxicity  [9],  oxygen-glucose
deprivation injury [10], and oxidative stress [11]. They also
prolonged the life span of cultured cortical neurons [12] and
promoted  neuronal  growth  [13,14].  Furthermore,  in  vivo
investigations demonstrated that HDACi protected neurons
exposed to intracerebral hemorrhage [15], ischemic stroke
[16],  and  in  chronic  neurodegenerative  diseases  [17-19].
Apart  from  HDAC  inhibition,  this  neuroprotective  effect
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395probably  involves  multiple  other  mechanisms  of  action,
including  modulation  of  the  extracellular  signal-regulated
kinase  pathway  [13]  and  the  inhibition  of  pro-apoptotic
molecules [16] or microglia-mediated inflammation [20].
Several  ophthalmologic  diseases  (e.g.,  experimental
glaucoma, acute optic nerve damage) lead to retinal ganglion
cell (RGC) death after changes in transcription of several
genes [21,22]. The involvement of histone deacetylation in
this pathology has recently been shown by Pelzel et al. who
reported a histone H4 deacetylation early after optic nerve
crush (ONC) in mice [23]. Yet there are few reports on the
effects of HDACi on RGCs. Schwechter et al. demonstrated
that TSA caused significant differentiation and neuritogenesis
of RGC-5 cells [24]. Recently, we detected a neuroprotective
effect of VPA on RGCs after ONC [25] but were unable to
verify changes in histone acetylation levels using western
blots.  However,  the  literature  clearly  indicates  HDAC
involvement in VPA-mediated activity. An interpretation for
this discrepancy is that the VPA-induced increase in histone
acetylation in RGCs was too small to be detected in full retinal
protein extracts because only the RGCs were damaged by
ONC, possibly resulting in a rather small signal-to-noise ratio
[25].
To overcome this problem, we therefore used purified
postnatal rat RGC cultures to quantify and pharmacologically
characterize the survival-promoting effect of SB, VPA, and
TSA  in  the  present  study.  In  addition  we  used
immunohistochemistry  to  quantify  the  expression  of
acetylated histone proteins (AcH) 3 and 4 in RGCs as markers
of HDACi-mediated hyperacetylation. The cell-death model
used in this experiment is based on apoptosis induced by
neurotrophic deprivation. It results from axotomy before RGC
harvesting.
METHODS
Cell culture: All animals were treated in accordance with the
Institute for Laboratory Animal Research (Guide for the Care
and Use of Laboratory Animals), and all procedures were
approved by the Committee of Animal Care of the University
of Freiburg. RGCs were purified by a modification [26] of
immunopanning with antibodies against Thy-1.1 specific for
RGCs and were cultured in serum-free medium, as previously
described [27,28]. Cell culture reagents were obtained from
Gibco Invitrogen Karlsruhe, Germany. In brief, rat (Charles
River,  Sulzfeld,  Germany)  retinas  were  extracted  from
newborn (postnatal day [P]0–P2) Sprague Dawley rats (three
pups per six retinas per attempt) and incubated at 37 °C for 20
min in 0.125% trypsin in Ca2+/Mg2+-free Hank’s balanced salt
solution. Enzyme treatment was stopped by washing the tissue
twice  with  Dulbecco’s  modified  eagle  medium  (DMEM
+GlutaMAX; Gibco Invitrogen) containing 10% horse serum,
10 mM Hepes, 100 units/ml penicillin G (sodium salt) and
100 μg/ml streptomycin sulfate, followed by centrifugation at
140 g for 2 min. To obtain a suspension of single cells, the
retinal  tissue  was  triturated  with  a  flame-narrowed  glass
pipette in 5 ml DMEM containing 10% horse serum.
Prior  to  this,  panning  dishes  (Falcon,  Becton  &
Dickinson, Heidelberg, Germany) were incubated with goat
antimouse immunoglobulin (IgG) antibodies (2 μg/ml; Sigma,
Munich, Germany) in Tris-HCl buffer (pH 9.5) for 12 h at
4  °C.  The  dishes  were  then  washed  three  times  with
Dulbecco's  phosphate-buffered  saline  (D-PBS)  without
magnesium or calcium (Cat. No. 14190–094, Gibco; D-PBS
contains potassium chloride 2.67 mM, potassium phosphate
monobasic 1.47 mM, sodium chloride 137.93 mM and sodium
phosphate dibasic 8.06 mM) followed by incubation with anti-
Thy-1.1 (0.8 μg/ml, mouse antirat CD90; Serotec, Düsseldorf,
Germany) for at least 2 h at 4 °C in PBS. After removal of the
supernatant, the retinal cell suspension was transferred to the
panning dish and incubated for 20 min at 37 °C. Dishes were
gently swirled every 5 min to ensure contact of all RGCs with
the surface of the plate. To remove nonadherent cells, dishes
were washed repeatedly with D-PBS and swirled moderately
until only adherent cells remained. Washing was monitored
under a microscope.
RGCs  were  mechanically  removed  from  the  panning
dishes in serum-free DMEM by using a cell scraper. After
centrifugation  at  140  g  for  5  min,  purified  RGCs  were
suspended in fresh culture medium and their density was
determined by counting an aliquot in a hemocytometer. The
cells  were  seeded  in  96-well  plates  (Greiner  Bio-One,
Frickenhausen, Germany) at a density of 3,000 cells per well
and incubated for 48 h at 37 °C in a humidified atmosphere
containing 5% CO2. Plates had been previously coated with
poly-D-lysine (0.1 mg/ml) followed by laminin (7.5 μg/ml) in
DMEM.
Histone  deacetylase  inhibitor  treatment:  Various
concentrations of HDACi (all from Sigma) were added to
culture medium in quadruplicates to hexaplicates per attempt:
SB 0.1, 0.5, 1, 5, 10 mM; VPA 0.1, 0.5, 0.75, 1, 2 mM; and
TSA 0.5, 1, 5, 10 nM. SB and VPA were dissolved in sterile
water and diluted with pure culture medium. Water-insoluble
TSA was dissolved in sterile DMSO (2 mg/ml), and further
diluted in methanol and medium. Negative controls of the SB
or VPA experiments were cultured in pure media. The TSA
control groups received the same amount of vehicle (DMSO
and methanol) without TSA. Positive controls were treated
with erythropoietin (EPO, Epoetin alfa; Janssen-Cilag GmbH,
Neuss, Germany) at concentrations of 0.05 IU/µl, 0.1 IU/µl,
0.2 IU/µl, and 0.4 IU/µl, as the neuroprotective potential of
EPO has been extensively evaluated in cultures of RGCs and
animal models of optic nerve diseases [29-31].
Quantification of viable retinal ganglion cells: After a culture
period  of  2  days,  RGC  cultures  were  fixed  in  1%
glutaraldehyde, rinsed with water, and examined unblinded
by  phase-contrast  microscopy.  The  number  of  surviving
RGCs was assessed by whole-well counts. Viable ganglion
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396cells were morphologically identified by their phase-bright
appearance, intact cell bodies with smooth membranes, and
neuritic processes.
Immunohistochemistry: For immunohistochemistry, a single
RGC suspension was prepared as described above. Instead of
seeding the cells in 96-well plates, cells were placed in equal
parts into petriperm culture dishes (Greiner Bio-One GmbH).
These dishes have a clear gas-permeable base membrane.
After culturing with or without 0.1 mM SB or 0.1 mM VPA
over 24 h, cells on the membrane were fixed using ice-cold
methanol (−20 °C) for 10 min. Immunohistochemistry was
performed after nonspecific binding was blocked with 10%
fetal calf serum for 30 min. After washing with D-PBS, cells
were  incubated  with  anti-Thy-1.1  (dilution  1:50,  Serotec)
overnight at 4 °C to identify RGCs, as it was not possible to
avoid minor contamination of the cell suspension with other
retinal  cells.  Thy-1.1  was  then  conjugated  with  the
corresponding  rhodamin  secondary  antibody  (red
fluorescence,  dilution  1:50;  KPL,  Gaithersburg,  MD).
Thereafter,  the  protocol  was  repeated,  and  anti-AcH3
(dilution 1:600; Cell Signaling, Danvers, MA) or anti-AcH4
(dilution 1:200; Cell Signaling) was used as a second primary
antibody to investigate the acetylation level in RGCs, with or
without  HDACi  treatment.  AcH3  or  AcH4  was  then
conjugated  with  Cy2™  secondary  antibody  (green
fluorescence, dilution 1:80; Jackson ImmunoResearch, West
Grove,  PA).  Subsequently,  the  base  membranes  of  the
petriperm  dishes  were  cut  and  covered  with  embedding
medium (Mowiol; Calbiochem, San Diego, CA).
Acetylation densitometry: Cells were photographed under a
fluorescence  microscope  (Axiophot;  Carl  Zeiss,  Jena,
Germany) in a linear modus, using the software of Carl Zeiss
Axio vision (Axio Rel. 4.7; Carl Zeiss). The same exposure
time  was  used  for  all  photographs  per  experiment.  The
expression pattern of AcH3 and AcH4 in RGCs was compared
with and without SB or VPA treatment after 24 h in culture
using ImageJ software (Bethesda, MD; open-label analysis).
AcH3- or AcH4-positive RGCs were localized through their
additional  Thy-1.1  immunoreactivity.  Single  AcH3/4-
positive  RGCs  were  encircled  with  the  ImageJ  elliptical
selection tool. After calibration of the cell-signal threshold by
determining background staining, the number of pixels per
gray  tone  was  counted  and  totaled  for  each  cell  (n=3
experiments, 60 cells per group) to determine an intensity
value per cell. The mean intensity value of each group of SB/
VPA-treated RGCs was divided by the mean intensity value
of the corresponding control RGCs (pure media). A quotient
of >1 represents a hyperacetylation in SB/VPA-treated RGCs;
a quotient of 1 means that AcH3/AcH4 was equally expressed
in  both  groups;  and  a  quotient  of  <1  represents  a
hypoacetylation in RGCs after treatment.
Statistical analysis: All averages are presented as means with
their  corresponding  standard  error  of  the  mean  (SEM).
Statistical significance was assessed using the unpaired t test
(immunohistochemistry) or ANOVA, followed by Tukey–
Kramer post hoc testing for multiple comparison procedures
(cell-culture experiments). GraphPad InStat and GraphPad
Prism software (La Jolla, CA) were used. Differences were
considered significant at p<0.05.
RESULTS
Cell culture and identification of retinal ganglion cells: The
numbers  of  viable  RGCs  per  well  were  counted  with  or
without drug treatment after 48 h in culture, using phase-
contrast microscopy. RGCs can be discriminated from other
retinal cells by their large cell diameter and fine neurites with
branching  growth  cones  (Figure  1,  white  arrows).
Degenerated apoptotic RGCs (see asterisk in Figure 1A) were
not counted. Despite extensive washing of the panning plate
after binding of RGCs to the Thy-1.1-coated plate, a small
number of other retinal cells (Figure 1, black arrows) were
still present in culture in each group.
Histone  deacetylase  inhibitor-induced  neuroprotection  of
retinal ganglion cells: Figure 2 shows the dose-dependent
Figure 1. Viable purified retinal ganglion cells in culture after 48 h. A, B: Representative phase contrast micrographs showing retinal ganglion
cell (RGC) controls (A, pure media) and RGCs after treatment with histone deacetylase inhibitors (HDACi; B, VPA) after 48 h in culture.
RGCs (white arrows) can be discriminated from other retinal cells (black arrows) by their large cell diameter and fine neurites with branching
growth cones, thus fulfilling the criteria for being counted as viable RGCs. Larger numbers of degenerated RGCs (asterisk in A) were present
in the control wells. Each scale bar is 50 µm.
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397effect of HDACi on RGC survival after 48 h in culture (n=4–
6 culture experiments at each concentration). Compared to
controls (pure media), VPA 0.1 and 0.5 mM significantly
increased  RGC  survival  to  163%  (p<0.01)  and  157%
(p<0.05), respectively. While VPA 0.75 and 1.0 mM had no
protective  effect  on  RGCs,  VPA  2.0  mM  significantly
decreased RGC survival to 22% (p<0.001, Figure 2A). SB
0.1  mM  significantly  increased  RGC  survival  to  188%
(p<0.001). A nonsignificant protective effect was seen with
SB 0.5 mM. SB 1.0 mM did not affect RGC survival in
comparison to control conditions. Higher concentrations of
SB (≥5 mM) significantly decreased RGC survival (Figure
2B). In contrast, TSA 0.5 or 1.0 nM had no effect on RGC
survival, while TSA 5 nM and 10 nM significantly decreased
RGC  survival  to  40%  (p<0.01)  and  8%  (p<0.001),
respectively (Figure 2C). EPO was used as a positive control
in this study in comparison to pure media (negative control).
EPO 0.05 IU/µl significantly increased RGC survival to 164%
(p<0.05), while higher concentrations were less effective but
did not harm RGCs. Figure 2E summarizes the statistically
significant neuroprotective effects of the HDACi compared
with that of EPO. Each column represents the increase in RGC
survival  (%)  after  drug  treatment  compared  to  individual
control  (neuroprotective  power=mean  cell  numbers
treatment/mean  cell  numbers  control*100).  VPA  0.1  and
0.5 mM and SB 0.1 mM had similar protective effects as EPO
0.05 IU/µl in this series of experiments.
Histone  deacetylase  inhibitor-induced  hyperacetylation  in
retinal ganglion cells: Immunohistochemistry was performed
to  determine  whether  HDACi  treatment  (SB  and  VPA
0.1 mM) increased the amount of AcH3 and AcH4 in RGCs.
Figure  3  shows  representative  photographs  of  anti-AcH3
(green)-  and  anti-Thy-1.1  (red)-labeled  RGCs  of  controls
(Figure 3A-C) and after SB treatment (Figure 3D-F). Thy-1.1
immunolabeling  was  used  to  specifically  identify  RGCs
(white arrows) among other retinal cells (black arrowheads).
Figure 2. Retinal ganglion cell survival. A-D: Graphs showing the dose-dependent effect of histone deacetylase inhibitors and erythropoietin
on retinal ganglion cell (RGC) survival after 48 h in culture. Data are presented as means and standard error of the mean (each diagram
summarizes  four  to  six  culture  experiments;  each  of  the  experiments  tested  the  drug  in  quadruplicates  to  hexaplicates  of  indicated
concentrations). A: Compared with untreated controls, valproic acid (VPA) 0.1 and 0.5 mM significantly increased RGC survival to 163%
(**p<0.01) and 157% (*p<0.05), respectively. Higher VPA concentrations (0.75 and 1.0 mM) had no protective effect, while VPA 2 mM
significantly decreased RGC survival to 22% (p<0.001). B: Sodium butyrate (SB) 0.1 mM significantly increased RGC survival to 188%
(***p<0.001), while a nonsignificant protective effect was seen with SB 0.5 mM. SB 1.0 mM did not affect RGC survival compared to controls.
Higher concentrations of SB (≥5 mM) significantly decreased RGC survival. C: Trichostatin A (TSA) 0.5 and 1.0 nM had no effect on RGC
survival, while TSA 5 nM and 10 nM significantly decreased RGC survival to 40% (p<0.01) and 8% (p<0.001), respectively. D: Erythropoietin
(EPO) 0.05 IU/µl increased RGC survival to 164% (*p<0.05), while higher concentrations of EPO were less effective. E: Histone deacetylase
inhibitors (HDACi: VPA 0.1 and 0.5 mM and SB 0.1 mM) had similar protective effects as EPO in this series of experiments (each column
represents the increase in RGC survival [%] after HDACi treatment compared to individual controls [neuroprotective power=mean cell
numbers treatment/mean cell numbers control*100]).
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398The  intensity  of  AcH3  and  AcH4  expression  was
quantified in RGCs with or without HDACi treatment by
determining  the  total  number  of  pixels  per  graytone  over
threshold after 24 h in culture. Figure 4 shows all four groups
with  their  corresponding  negative  controls.  Data  of  60
randomly chosen RGCs from three experiments per group are
presented. In comparison to controls, SB 0.1 mM significantly
increased AcH3 (17,101±1,169 versus 29,073±4,540 pixels
per  graytone/RGC,  p=0.0119;  Figure  4A)  and  AcH4
(13,052±1,203  versus  17,616±1,279  pixels  per  graytone/
RGC, p=0.0105; Figure 4C) levels in RGCs, respectively. The
expression quotients were 1.7 and 1.4, respectively, indicating
an apparent increase of AcH3 and AcH4 in RGCs after SB
treatment.  Compared  with  the  controls,  VPA  slightly
increased AcH3 (11,544±1,061 versus 13,913±1,173 pixels
per  graytone/RGC,  p=0.1368;  Figure  4B)  and  AcH4
(14,598±1,371  versus  16,251±1,004  pixels  per  graytone/
RGC,  p=0.3326;  Figure  4D)  levels  over  baseline  levels;
however, the differences were not statistically significant (the
expression quotients were 1.2 and 1.1, respectively).
DISCUSSION
The  neuroprotective  potential  of  HDACi  has  not  been
evaluated extensively in cultures of RGCs or animal models
of optic nerve diseases. In this study we tested the effect of
three HDACi on the survival of purified postnatal RGCs,
which underwent spontaneous cell death over time in culture.
The main findings can be summarized as follows: (1) SB and
VPA enhanced RGC survival in culture to 188% and 163%,
respectively, with both substances showing a maximum effect
at 0.1 mM; (2) the neuroprotective effects of SB and VPA
were comparable to that of EPO 0.05 IU/µl; (3) TSA 0.5–1.0
nM did not affect RGC survival but increased cell death in
concentrations  ≥5  nM;  (4)  AcH3  and  AcH4  levels  were
significantly higher in RGCs treated with SB 0.1 mM, while
VPA  0.1  mM  produced  only  a  slight  effect  on  histone
acetylation.
The  role  of  protein  acetylation  has  emerged  as  an
important  posttranslational  modification  that  regulates
multiple cellular functions, including chromatin remodeling
and  transcriptional  regulation  [3,7].  The  upregulation  of
transcription via hyperacetylation can be achieved in cells
either by stimulating HAT or inhibiting HDAC. HDAC have
recently  been  recognized  as  potentially  useful  therapeutic
targets in a broad range of human disorders. Pharmacological
manipulations using HDACi have been beneficial in various
experimental  models  of  central  nervous  system  diseases
[15-18,32].
VPA and SB are short-chain fatty acids that readily cross
the blood–brain barrier. They have been found to have low
toxicity and acceptable tolerability in both human and animal
studies [33,34]. We previously detected a neuroprotective
effect  of  VPA  on  RGCs  after  ONC  [25].  In  the  current
investigation  using  for  the  first  time  postnatal  rat  RGC
Figure 3. Hyperacetylation in retinal ganglion cells after histone deacetylase inhibitor treatment. Representative photographs of anti-acetylated
histone proteins (AcH3; green)- and anti-Thy-1.1 (red)- labeled retinal ganglion cells (RGCs) of controls (A-C) and after sodium butyrate
(SB) treatment (D-F). Thy-1.1 immunolabeling was used to specifically identify RGCs (white arrows) among other retinal cells (black
arrowheads). In comparison to the control, the AcH3 immunoreactivity seems upregulated in RGCs after SB treatment. The scale bar in F is
for all pictures and represents 100 µm. The insets show a single RGC at a higher magnification.
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399cultures, we found that VPA 0.1 and 0.5 mM and SB 0.1 mM
significantly increased RGC survival. VPA 0.75 and 1.0 mM
and SB 0.5 and 1.0 mM had no impact on RGC survival, while
VPA ≥2 mM and SB ≥5 mM significantly decreased levels of
viable  RGCs  (Figure  2A,B).  These  results  are  partly
consistent  with  previous  in  vitro  studies  that  showed  a
neuroprotective effect of VPA in cultures of cerebral cortical
neurons (CCN) [12] or cerebellar granule cells (CGC) [9],
with  a  maximum  effect  at  concentrations  of  0.5  mM  or
1.6 mM, respectively. VPA concentrations of 0.1 to 0.4 mM
and 0.75 to 1.0 mM tested in these experiments were found to
be  less  efficient  but  still  neuroprotective,  while  VPA
concentrations  >1.6  mM  were  not  determined  [9,12].  SB
protected CGC from excitotoxicity in concentrations ranging
from 0.125 to 1.0 mM [9]. The neuroprotective effect of VPA
on RGCs occurred at therapeutic concentrations used for the
treatment  of  bipolar  disorder  and  seizures  [35].  The
neuroprotective potential of VPA and SB was comparable to
that  of  EPO,  an  established  neuroprotectant  for  RGCs
[29-31].  Interestingly,  the  VPA-/SB-mediated  RGC
protection was not mimicked by TSA, a particularly potent
HDACi. In the present investigation, TSA 0.5–1.0 nM had no
impact  on  RGC  survival  but  increased  cell  death  in
concentrations  ≥5  nM.  Previous  studies  have  likewise
revealed marked toxic effects of TSA 100 nM in neuronal cells
[36]  and  of  TSA  100,  300,  and  600  nM  in  cultured
dopaminergic neuronal cells [37]. Lower doses of TSA (1.0–
10 nM) were insufficient [36]/less sufficient [37] to trigger
cell  death.  By  contrast,  other  authors  have  reported  a
neuroprotective effect of TSA in the following concentrations
and cells: 10–30 nM in CCN cultures [12] and 25–100 nM in
CGC cultures [9]. Furthermore, Schwechter et al. reported
significant differentiation and neuritogenesis of RGC-5 cells
after exposure to TSA 500 nM [24], and Pelzel et al. found an
Figure 4. Increased acetylated histone 3 and acetylated histone 4 levels in retinal ganglion cells after histone deacetylase inhibitor treatment.
A-D: Intensity of acetylated histone (AcH) 3 and AcH4 expression in retinal ganglion cells (RGCs) with or without histone deacetylase
inhibitor (HDACi) treatment after 24 h in culture. A, C: In comparison to controls, sodium butyrate (SB) 0.1 mM significantly increased the
amount of AcH3 (A, *p=0.0119) and AcH4 (C; *p=0.0105) in RGCs. The expression quotients were 1.7 and 1.4, respectively, indicating an
apparent hyperacetylation after SB treatment. The horizontal line in A+C indicates, that the difference in hyperacetylation was statistically
significant. B, D: Valproic acid (VPA) slightly increased AcH3 (B, p=0.1368) and AcH4 (D, p=0.3326) over baseline levels in controls;
however, differences were not statistically significant (the expression quotients were 1.2 and 1.1, respectively).
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400attenuated cell loss in the ganglion cell layer of mice after a
1 mg/kg intraperitoneal injection of TSA before ONC [23]. In
summary,  HDACi  have  mainly  been  tested  as  potential
therapeutics  for  neurodegenerative  disorders  and  in  most
cases have shown dose-dependent neuroprotective effects.
However, in some cases HDACi seem to play a role in the
pathogenesis of neurodegenerative diseases. This may depend
on  factors  such  as  epigenetic  status,  cell  type,  and  tissue
specificity.
What is the basis on which SB and VPA act in this model?
At present there are few data on epigenetic approaches using
HDACi in the treatment of ophthalmological diseases, and the
pharmacological  characteristics  of  HDACi-induced
protection of RGCs have not yet been elaborated. One of the
first documentations of epigenetic changes (increased HDAC
activity and decreased H4 acetylation) associated with RGC
death after ONC in mice was just recently published by Pelzel
et al. [23]. VPA and SB were recently found to be direct
inhibitors of HDAC at clinically relevant concentrations [8,
38]. The VPA-induced neuroprotection in neuronal cultures
was therefore associated with a robust increase in AcH3 levels
[9,12,39]. In the present investigation, SB and VPA but not
TSA  enhanced  RGC  survival,  although  AcH3  and  AcH4
levels were only significantly higher in RGCs treated with SB.
Thus, histone acetylation might play a subordinate role next
to  other  potential  neuroprotective  pathways  acting  in  this
model.
In our recent study, the VPA-mediated neuroprotection
after ONC was accompanied by decreased caspase-3 activity,
cyclic adenosine monophosphate (cAMP) response element
binding  protein  (CREB)  induction,  and  phosphorylated
extracellular signal-regulated kinase (pERK) 1/2 activation
but not by altered histone acetylation, as shown in western
blots [25]. In addition to histone acetylation, HDACi have
been reported to exert neuroprotective effects by enhancing
the acetylation of cytoprotective transcription factors and by
inhibiting some forms of apoptosis [40]. VPA treatment, for
example, dramatically enhanced the acetylation of nuclear
factor-kappa-light-chain-enhancer of activated B-cells (NF-
kB) in neuronal cells kept under hypoxia for 6 h [39]. The anti-
apoptotic activity of NF-kB was mediated by inducing the
transcription  of  several  anti-apoptotic  genes  [39].
Furthermore, VPA has been shown to protect CCN against
low  K+-induced  apoptosis  by  acting  on  the
phosphatidylinositol 3-kinase/protein kinase B pathway [41]
and  to  activate  the  ERK  pathway,  thereby  inducing  ERK
pathway-mediated  neurotrophic  actions,  such  as  neurite
growth, regeneration, and neurogenesis [13,25]. The more
recent data on VPA neuroprotective mechanisms in models of
neurodegenerative diseases were summarized by Monti and
colleagues [42] who demonstrated that VPA affects several
fundamental  cellular  processes  by  targeting  multiple
molecular mechanisms. Moreover, beside direct effects of
HDACi  on  neurons,  recent  reports  have  shown  their
immunomodulatory action on microglia [20,43]. VPA, TSA,
and  SB  have  been  shown  to  induce  an  apoptosis-related
decrease  of  cultured  rat  microglia,  which  occurs  with  a
reduced neuroinflammatory response in lipopolysaccharide
(LPS)-treated  neuron-glia  cultures,  thereby  acting
neuroprotectively [44]. Additional studies are necessary to
identify  HDACi-targeted  genes  and  pathways  involved  in
RGC protection.
Our study has some limitations. First, it raises no claim
to  completeness  regarding  the  analysis  of  acetylation-
associated  processes.  Therefore,  the  hypothesis  of  RGC
protection through hyperacetylation should not be rejected.
We only analyzed the acetylation levels of histone proteins 3
and 4, which were described as the most commonly involved
histones that are altered in models of neurodegeneration. To
further characterize the role of modulated histone acetylation
in models of optic nerve injury, e.g., other histone proteins
and, the activity of HAT and HDAC should be examined as
well as the acetylation of cytoprotective transcription factors.
However, due to limited amounts of sample material available
for further molecular investigation using purified postnatal
RGC cultures, other in vivo models should be used to identify
HDACi-associated  pathways  and  mechanism  involved  in
RGC protection. Another point of criticism is that VPA and
SB had only little therapeutic range, with higher doses causing
RGC degeneration. Instead of being neuroprotective, VPA
can even exacerbate neuronal death under some conditions
[45]. A possible explanation with regard to acetylation is that
the modes of action of HDACi are highly nonspecific and
nontargeted;  they  may  reverse  the  deacetylation-mediated
blockade of undesirable nonspecific promoters, leading to
cytotoxicity. These findings suggest a need for caution in
studies that attempt to examine the molecular mechanisms of
HDACi-mediated  neuroprotection.  Another  potential
shortcoming of this investigation is its open-label design due
to logistical reasons. We tried to circumvent this problem by
carrying along two control groups, a negative cohort with
media alone and a second cohort with an effective treatment
(EPO). Furthermore, the morphologic characteristics of viable
RGCs were clearly defined.
Taken  together,  HDACi  VPA  and  SB  are  promising
candidates  to  counteract  neuronal  loss  in  the  brain  and
possibly in ophthalmological diseases. The present study is
the  first  to  detect  HDACi-mediated  hyperacetylation  in
purified rat RGCs, although significantly elevated AcH3 and
AcH4 levels were only present in RGCs after SB treatment.
Further studies are needed to identify HDACi-targeted genes
and pathways involved in RGC protection and to assess in
detail the biologic potency, safety, and pharmacotoxicity of
these drugs with regard to the retina.
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